HuGE Literature Finder
|
||
Records 1-100
|
Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit.
Indian heart journal 2018 Dec 70 Suppl 3 S13-S19. Biswas Mansij, Bendkhale Shital R, Deshpande Siddharth P, Thaker Saket J, Kulkarni Dwarkanath V, Bhatia Shobna J, Rajadhyaksha Anjali G, Gogtay Nithya J, Thatte Urmila |
|
Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China.
Pediatric cardiology 2018 Aug . Yang Dan, Kuang Hongyu, Zhou Yuanlin, Cai Chunqiong, Lu Tiew |
|
Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD).
European journal of clinical pharmacology 2018 May . Nakagita Kazuki, Wada Kyoichi, Mukai Yutaro, Uno Takaya, Nishino Ryoji, Matsuda Sachi, Takenaka Hiromi, Terakawa Nobue, Oita Akira, Takada Mitsuta |
|
Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.
European journal of clinical investigation 2018 Mar e12929. Serna María José, Rivera-Caravaca José Miguel, Gonzalez-Conejero Rocío, Esteve-Pastor María Asunción, Valdés Mariano, Vicente Vicente, Lip Gregory Y H, Roldán Vanessa, Marín Francis |
|
Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
Vascular pharmacology 2018 Feb . Bryk Agata Hanna, Wypasek Ewa, Plens Krzysztof, Awsiuk Magdalena, Undas Anet |
|
Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
European journal of clinical pharmacology 2018 Feb . Ajmi Marwa, Omezzine Asma, Achour Slim, Amor Dorra, Hamdouni Haithem, Ismaïl Fatma Ben Fredj, Rejeb Nabila Ben, Kechrid Chedia Laouani, Boughzela Essia, Bouslama A |
|
The rs2108622 polymorphism is related to the early risk of ischemic stroke in non-valvular atrial fibrillation subjects under oral anticoagulation.
The pharmacogenomics journal 2017 Dec . Colàs-Campàs L, Royo J L, Montserrat M V, Marzo C, Molina-Seguín J, Benabdelhak I, Cambray S, Purroy |
|
Identification of Novel Variants Associated with Warfarin Stable Dosage Using a Two-stage Extreme Phenotype Strategy.
Journal of thrombosis and haemostasis : JTH 2016 Oct . Luo Zhiying, Li Xi, Zhu Mingfeng, Tang Jie, Li Zhi, Zhou Xinming, Song Guobao, Liu Zhaoqian, Zhou Honghao, Zhang W |
|
Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?
Drug metabolism and personalized therapy 2016 Jul . Falvella Felicia Stefania, Marelli Susan, Cheli Stefania, Montanelli Stefano, Viecca Federico, Salvi Lucia, Ferrara Alfio, Clementi Emilio, Trifirò Giuliana, Pini Alessand |
|
Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 Jun . Kalpana S R, Bharath G, Manjunath C N, Christopher Ri |
|
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
Thrombosis and haemostasis 2016 May 116 (2): . Whitlock Richard P, Whitlock Richard, Fordyce Christopher B, Midei Mark G, Ellis Dave, Garcia David, Weitz Jeffrey I, Canafax Daniel M, Albrecht Detlef, Milner Peter |
|
[Establishment and evaluation of a warfarin-dosing algorithm in Chinese Han population].
Zhonghua yi xue za zhi 2016 Mar 96 (10): 776-80. Li C B, Dai D P, Hu G X, Pu C W, Cao Y P, Cai J |
|
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.
Pharmacogenomics 2016 Feb . Schirmer Jan Henrik, Bremer Jan Phillip, Moosig Frank, Holle Julia Ulrike, Lamprecht Peter, Wieczorek Stefan, Haenisch Sierk, Cascorbi Ingo |
|
Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement.
Cellular and molecular biology (Noisy-le-Grand, France) 2016 62 (1): 51-5. Kirac D, Erdem A, Avcilar T, Yesilcimen K, Guney A I, Emre A, Yazici S, Terzi S, Kaspar E C, Cetin S E, Isbir |
|
CYP2C8 rs17110453 and EPHX2 rs751141 two-locus interaction increases susceptibility to ischemic stroke.
Gene 2015 Jul 565 (1): 85-9. Yi Xingyang, Zhang Biao, Wang Chun, Liao Duanxiu, Lin Jing, Chi Lif |
|
Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2015 Jul 26 (5): 499-504. Ghozlan Manal F, Foad Dina A, Darwish Yasser W, Saad Abeer |
|
Influence of UDP-glucuronosyltransferase polymorphisms on stable warfarin doses in patients with mechanical cardiac valves.
Cardiovascular therapeutics 2015 Jul . An Sook Hee, Chang Byung Chul, Lee Kyung Eun, Gwak Hye S |
|
Race influences warfarin dose changes associated with genetic factors.
Blood 2015 Jul 126 (4): 539-45. Limdi Nita A, Brown Todd M, Yan Qi, Thigpen Jonathan L, Shendre Aditi, Liu Nianjun, Hill Charles E, Arnett Donna K, Beasley T Ma |
|
Genetic polymorphisms of ALOX5AP and CYP3A5 increase susceptibility to ischemic stroke and are associated with atherothrombotic events in stroke patients.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2015 Mar 24 (3): 521-9. Yi Xingyang, Zhang Biao, Wang Chun, Liao Duanxiu, Lin Jing, Chi Lif |
|
Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population.
Pharmacological reports : PR 2015 Feb 67 (1): 97-101. Arun Kumar Annan Sudarsan, Kumar Srinivasamurthy Suresh, Umamaheswaran Gurusamy, Kesavan Ramasamy, Balachandar Jayaraman, Adithan Chandrasekar |
|
Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2015 Feb 35 (2): 267-76. Donnelly Mark K, Conley Yvette P, Crago Elizabeth A, Ren Dianxu, Sherwood Paula R, Balzer Jeffery R, Poloyac Samuel |
|
[CLINICAL AND PHARMACOLOGICAL FACTORS INFLUENCING RESISTANCE TO CLOPIDOGREL IN PATIENTS WITH CARDIOVASCULAR DISEASES].
Klinicheskaia meditsina 2015 93 (2): 40-6. Mesitskaia D F, Nikitina Iu M, Kopylov F Iu, Syrkin A L, Aksenova M G, Kirillov M Iu, Dobrovol'ski? A |
|
[Comparison of Empiric and Pharmacogenetic Approaches in Assessment of Efficacy of Anticoagulant Therapy].
Kardiologiia 2015 55 (4): 57-60. Kokh N V, Slepukhina A A, Tsvetovskaya G A, Lifshits G |
|
[HAS-BLED and HEMORR2HAGES Scales in Assessment of Bleeding Risk in Patients on Long-Term Warfarin Therapy].
Kardiologiia 2015 55 (9): 50-6. Moreva O V, Kropacheva E S, Panchenko E P, Dobrovolsky A B, Zemlyanskaya O A, Donnikov A E, Titaeva E V, Guskova I |
|
Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study.
Molecular diagnosis & therapy 2014 Dec 18 (6): 675-83. de Oliveira Almeida Vanessa Cristina, Ribeiro Daniel Dias, Gomes Karina Braga, Godard Ana Lúcia Brunial |
|
Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
Pharmacogenetics and genomics 2014 Oct 24 (10): 501-13. Jiménez-Varo Enrique, Cañadas-Garre Marisa, Gutiérrez-Pimentel María J, Calleja-Hernández Miguel |
|
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis.
Journal of thrombosis and haemostasis : JTH 2014 Sep 12 (9): 1480-7. Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci P |
|
Pharmacogenetics role in the safety of acenocoumarol therapy.
Thrombosis and haemostasis 2014 Sep 112 (3): 522-36. Jiménez-Varo E, Cañadas-Garre M, Henriques C I, Pinheiro A M, Gutiérrez-Pimentel M J, Calleja-Hernández M |
|
Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
Journal of the neurological sciences 2014 Aug 343 (1-2): 30-5. Supe Svjetlana, Božina Nada, Matijevi? Vesna, Bazina Antonela, Mišmaš Antonija, Ljevak Josip, Alvir Domagoj, Habek Mario, Poljakovi? Zdrav |
|
[Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population].
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2014 Jun 31 (3): 367-71. Lou Ying, Han Lulu, Li Yan, Zhang Xiaoxing, Liu Zhihong, Tang Min, Yu Haiwen, Wang Wei, Xu Jianping, Liu Hong, Li Yis |
|
Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
Irish journal of medical science 2014 Jun 183 (2): 161-72. Bazan N S, Sabry N A, Rizk A, Mokhtar S, Badary O |
|
VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2014 Jun . Azzam Hanan, Elwakeel Hossam, Awad Ibrahim, El-Farahaty Reham, El-Gilany Abdel-Hady, El-Sharawy Sola |
|
Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis.
Thrombosis research 2014 May 133 (5): 729-35. De Tanima, Christopher Rita, Nagaraja Dindag |
|
Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese.
Neuroreport 2014 May 25 (7): 452-7. Chi Li-Fen, Yi Xing-Yang, Shao Min-Jie, Lin Jing, Zhou Qia |
|
Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
European journal of clinical pharmacology 2014 Jan 70 (1): 47-56. Krishna Kumar Dhakchinamoorthi, Shewade Deepak Gopal, Loriot Marie-Anne, Beaune Philippe, Balachander Jayaraman, Sai Chandran B V, Adithan Chandrasekar |
|
The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery.
Journal of thrombosis and thrombolysis 2014 37 (2): 177-85. Tatarunas Vacis, Lesauskaite Vaiva, Veikutiene Audrone, Grybauskas Pranas, Jakuska Povilas, Jankauskiene Laima, Bartuseviciute Ruta, Benetis Rimant |
|
[A randomized controlled study of the VKORC1 and CYP2C9 genotypes in guiding warfarin therapy for pulmonary thromboembolism].
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2013 Dec 36 (12): 950-3. Li Jie, Liu Shuang, Yang Jing-hua, Guo Wei, Wang Zeng-zhi, Chen Yong, Wang Sheng-h |
|
A randomized trial of genotype-guided dosing of warfarin.
The New England journal of medicine 2013 Dec 369 (24): 2294-303. Pirmohamed Munir, Burnside Girvan, Eriksson Niclas, Jorgensen Andrea L, Toh Cheng Hock, Nicholson Toby, Kesteven Patrick, Christersson Christina, Wahlström Bengt, Stafberg Christina, Zhang J Eunice, Leathart Julian B, Kohnke Hugo, Maitland-van der Zee Anke H, Williamson Paula R, Daly Ann K, Avery Peter, Kamali Farhad, Wadelius Mia, |
|
An acenocoumarol dose algorithm based on a South-Eastern European population.
European journal of clinical pharmacology 2013 Nov 69 (11): 1901-7. Pop Tudor Radu, Vesa ?tefan Cristian, Trifa Adrian Pavel, Cri?an Sorin, Buzoianu Anca Da |
|
Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Pharmacogenetics and genomics 2013 Nov 23 (11): 611-8. Wolkanin-Bartnik Jolanta, Pogorzelska Hanna, Szperl Ma?gorzata, Bartnik Aleksandra, Koziarek Jacek, Bilinska Zofia |
|
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
JACC. Cardiovascular interventions 2013 Nov 6 (11): 11. Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G |
|
Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2013 Aug 44 (2): 309-14; discussion 314-5. Brehm Kerstin, Schack Jenny, Heilmann Claudia, Blanke Philipp, Geissler Hans Joachim, Beyersdorf Friedhe |
|
Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.
Thrombosis and haemostasis 2013 Jul 110 (1): 131-40. Franken Cora C, Kaiser Andreas F C, Krüger Jan C, Overbeck Kristina, Mügge Andreas, Neubauer Hor |
|
Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?
Clinical medicine & research 2013 Jun 11 (2): 73-9. Glurich Ingrid, Berg Richard L, Burmester James |
|
Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
European journal of pharmacology 2013 Jun 710 (1-3): 80-4. Gaikwad Tejasvita, Ghosh Kanjaksha, Kulkarni Bipin, Kulkarni Vrinda, Ross Cecil, Shetty Shrima |
|
Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.
Clinical pharmacokinetics 2013 May 52 (5): 359-71. Abduljalil Khaled, Lazar Simone, Natanzon Michael, Wu Weidong, Zadoyan Gregor, Steffens Benedict, Kohl Victoria, Mörike Klaus, Tomalik-Scharte Dorota, Stingl Julia, Schwab Matthias, Harenberg Job, Gleiter Christoph, Fuhr U |
|
The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin.
Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina 2013 Feb 10 (1): 1. Ucar M, Alagozlu H, Sahin S, Ozdemir O |
|
Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response.
Genetics and molecular research : GMR 2013 12 (4): 4413-21. Nastasi-Catanese J A, Padilla-Gutiérrez J R, Valle Y, Ortega-Gutiérrez F, Gallegos-Arreola M P, Figuera L |
|
Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.
PloS one 2013 8 (8): e71505. Mazzaccara Cristina, Conti Valeria, Liguori Rosario, Simeon Vittorio, Toriello Mario, Severini Angelo, Perricone Corrado, Meccariello Alfonso, Meccariello Pasquale, Vitale Dino Franco, Filippelli Amelia, Sacchetti Luc |
|
Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.
Trials 2012 Dec 13 (1): 1. Carcas AJ, Borobia AM, Velasco M, Abad-Santos F, Díaz MQ, Fernández-Capitán C, Ruiz-Giménez N, Madridano O, Sillero PL |
|
Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
The Journal of the Association of Physicians of India 2012 Dec 60 34-8. Shalia Kavita K, Doshi Shripal M, Parikh Suhas, Pawar Poonam P, Divekar Siddhi S, Varma Sandeep P, Mehta Rachna, Doctor Tasneem, Shah Vinod K, Saranath |
|
Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.
Pathologie-biologie 2012 Nov . Smires FZ, Habbal R, Moreau C, Assaidi A, Loriot MA, Nadifi S |
|
Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations.
Frontiers in genetics 2012 3 . Roco A, Quiñones L, Agúndez JA, García-Martín E, Squicciarini V, Miranda C, Garay J, Farfán N, Saavedra I, Cáceres D, Ibarra C, Varela N |
|
Genetic and Clinical Determinants Influencing Warfarin Dosing in Children With Heart Disease.
Pediatric cardiology 2012 Nov . Nguyen N, Anley P, Yu MY, Zhang G, Thompson AA, Jennings LJ |
|
Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients.
Seizure : the journal of the British Epilepsy Association 2012 Nov . Phabphal K, Geater A, Limapichart K, Sathirapanya P, Setthawatcharawanich S |
|
CYP2C9 and VKORC1 Gene Polymorphism is Inessential for Bleeding Development under Conditions of Oral Application of Anticoagulant Acenocoumarol in Russian Patients at High Risk of Thromboembolic Complications.
Bulletin of experimental biology and medicine 2012 Oct 153 (6): 6. Sychev DV, Ignatyev IV, Emelyanov NV, Milovanova VV, Kossovskaya AV, Kukes IV, Tashenova AI, Kukes VG |
|
Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.
Journal of clinical pharmacy and therapeutics 2012 Oct 37 (5): 594-8. Smires F Z, Moreau C, Habbal R, Siguret V, Fadili S, Golmard J L, Assaidi A, Beaune P, Loriot M A, Nadifi |
|
Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
Journal of human genetics 2012 Oct 57 (10): 665-9. Pathare Anil, Al Khabori Murtadha, Alkindi Salam, Al Zadjali Shoaib, Misquith Rhea, Khan Hammad, Lapoumeroulie Claudine, Paldi Andras, Krishnamoorthy Rajagop |
|
Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China.
Pharmacogenetics and genomics 2012 Sep . Wu H, Qian J, Xu J, Sun A, Sun W, Wang Q, Ge J |
|
A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Thrombosis and haemostasis 2012 Jun 107 (6): 1083-91. Wei Meng, Ye Fei, Xie Dujiang, Zhu Yubing, Zhu Junrong, Tao Yifu, Yu Fe |
|
White blood cells contribute to patient-specific warfarin dose for Han Chinese.
Chinese medical journal 2012 Jun 125 (11): 1960-3. Zhu Jin, Zheng Wen-Jie, Zhang Wei-Juan, Wang He-Yao, Wang Ch |
|
Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.
European journal of clinical pharmacology 2012 May 68 (5): 617-27. Mlynarsky Liat, Bejarano-Achache Idit, Muszkat Mordechai, Caraco Yose |
|
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.
Thrombosis research 2012 Apr 129 (4): 441-6. Kassimis George, Davlouros Periklis, Xanthopoulou Ioanna, Stavrou Eleana F, Athanassiadou Aglaia, Alexopoulos Dimitri |
|
A candidate gene approach to genetic contributors to the development of IgA nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2012 Mar 27 (3): 1020-30. Yamamoto Ryohei, Nagasawa Yasuyuki, Shoji Tatsuya, Katakami Naoto, Ohtoshi Kentaro, Hayaishi-Okano Rieko, Yamasaki Yoshimitsu, Yamauchi Atsushi, Tsubakihara Yoshiharu, Imai Enyu, Rakugi Hiromi, Isaka Yoshita |
|
Multivariate analysis of the relation between diet and warfarin dose.
European journal of clinical pharmacology 2012 Mar 68 (3): 321-8. Rasmussen Morten Arendt, Skov Jane, Bladbjerg Else-Marie, Sidelmann Johannes J, Vamosi Marianne, Jespersen Jørg |
|
Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.
Pharmacogenomics 2012 Feb 13 (3): 309-21. Zhang Wei, Zhang Wei-Juan, Zhu Jin, Kong Fan-Cui, Li Yan-Yan, Wang He-Yao, Yang Yuan-Hua, Wang Ch |
|
Validation of warfarin pharmacogenetic algorithms in clinical practice.
Pharmacogenomics 2012 Jan 13 (1): 21-9. Marin-Leblanc Mélina, Perreault Sylvie, Bahroun Imen, Lapointe Mathieu, Mongrain Ian, Provost Sylvie, Turgeon Jacques, Talajic Mario, Brugada Ramon, Phillips Michael, Tardif Jean-Claude, Dubé Marie-Pier |
|
Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.
Blood 2012 Jan 119 (3): 861-7. Moreau Caroline, Bajolle Fanny, Siguret Virginie, Lasne Dominique, Golmard Jean-Louis, Elie Caroline, Beaune Philippe, Cheurfi Radhia, Bonnet Damien, Loriot Marie-An |
|
An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.
PloS one 2012 7 (7): e41360. Borobia Alberto M, Lubomirov Rubin, Ramírez Elena, Lorenzo Alicia, Campos Armando, Muñoz-Romo Raul, Fernández-Capitán Carmen, Frías Jesús, Carcas Antonio |
|
[Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China].
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2011 Dec 43 (6): 798-803. Liu Yuan, Zhong Shi-long, Yang Min, Tan Hong-hong, Fei Hong-wen, Chen Ji-yan, Yu Xi-yong, Lin Shu-gua |
|
Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
Clinical therapeutics 2011 Oct 33 (10): 1371-80. Cho Hyun-Jung, On Young-Keun, Bang Oh Young, Kim Jong-Won, Huh Wooseong, Ko Jae-Wook, Kim June Soo, Lee Soo-Yo |
|
Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Journal of clinical pharmacology 2011 Oct 51 (10): 1418-28. Esmerian Maria O, Mitri Zahi, Habbal Mohammad-Zuheir, Geryess Eddy, Zaatari Ghazi, Alam Samir, Skouri Hadi N, Mahfouz Rami A, Taher Ali, Zgheib Nathalie |
|
Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.
Annals of hematology 2011 Jun 90 (6): 635-41. Gan Gin Gin, Phipps Maude E, Lee Michael M T, Lu Liang S, Subramaniam Rajallectchumy Y, Bee Ping C, Chang Sean |
|
Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients.
Drug metabolism and pharmacokinetics 2011 Jun 26 (3): 295-9. Kato Yuya, Ichida Fukiko, Saito Kazuyoshi, Watanabe Kazuhiro, Hirono Keiichi, Miyawaki Toshio, Yoshimura Naoki, Horiuchi Isao, Taguchi Masato, Hashimoto Yuki |
|
Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome.
Thrombosis research 2011 Jun 127 (6): 595-9. Ames Paul R J, Margaglione Maurizio, Ciampa Antonio, Colaizzo Donatella, Ferrara Felicetto, Iannaccone Luigi, Vincenzobrancacci |
|
[CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications].
Vestnik Rossi?sko? akademii meditsinskikh nauk / Rossi?skaia akademiia meditsinskikh nauk 2011 (3): 3. Authors are not available |
|
Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
Pharmacogenetics and genomics 2011 Mar 21 (3): 130-5. Shahin Mohamed Hossam A, Khalifa Sherief I, Gong Yan, Hammad Lamiaa N, Sallam Mohamed T H, El Shafey Mostafa, Ali Shawky S, Mohamed Mohamed-Eslam F, Langaee Taimour, Johnson Julie |
|
Pharmacogenomics of warfarin dose requirements in Hispanics.
Blood cells, molecules & diseases 2011 Feb 46 (2): 147-50. Cavallari Larisa H, Momary Kathryn M, Patel Shitalben R, Shapiro Nancy L, Nutescu Edith, Viana Marlos A |
|
[Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Terapevticheski? arkhiv 2011 83 (6): 59-65. Vorob'eva N M, Panchenko E P, Dobrovol'ski? A B, Titaeva E V, Khasanova Z B, Konovalova N V, Postnov A Iu, Kirienko A |
|
Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
International heart journal 2011 52 (1): 44-9. Miyagata You, Nakai Kenji, Sugiyama Yoshi |
|
Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
BMC medical genetics 2011 12 80. Suriapranata Ivet M, Tjong Wen Ye, Wang Tingliang, Utama Andi, Raharjo Sunu B, Yuniadi Yoga, Tai Susan |
|
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction.
Journal of biomedicine & biotechnology 2011 2011 739751. Kringen Marianne K, Haug Kari Bente Foss, Grimholt Runa M, Stormo Camilla, Narum Sigrid, Opdal Mimi S, Fosen Jan Toralf, Piehler Armin P, Johansen Per W, Seljeflot Ingebjørg, Berg Jens Petter, Brørs O |
|
Large-scale candidate gene analysis of HDL particle features.
PloS one 2011 6 (1): e14529. Kaess Bernhard M, Tomaszewski Maciej, Braund Peter S, Stark Klaus, Rafelt Suzanne, Fischer Marcus, Hardwick Robert, Nelson Christopher P, Debiec Radoslaw, Huber Fritz, Kremer Werner, Kalbitzer Hans Robert, Rose Lynda M, Chasman Daniel I, Hopewell Jemma, Clarke Robert, Burton Paul R, Tobin Martin D, Hengstenberg Christian, Samani Nilesh |
|
The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease.
Annals of clinical and laboratory science 2011 41 (3): 229-35. Moon Hee-Won, Noh Jaekwang, Yun Yeo-Min, Kim Hahn Young, Yun Ik Jin, Song Junghan, Kim Jin |
|
Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily).
The American journal of cardiology 2010 Dec 106 (11): 1588-93. Hu Miao, Lee Michael H K, Mak Valiant W L, Tomlinson Bri |
|
Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing.
Puerto Rico health sciences journal 2010 Dec 29 (4): 402-8. Rodríguez-Vélez Rosángela, Ortiz-Rivera Oscar J, Bower Bruce, Gorowski Krystyna, Windemuth Andreas, Villagra David, Kocherla Mohan, Seip Richard L, D'Agostino Darrin, Vergara Cunegundo, Ruaño Gualberto, Duconge Jor |
|
In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
Blood 2010 Dec 116 (26): 6101-5. Nowak-Göttl Ulrike, Dietrich Kevin, Schaffranek Daria, Eldin Noha Sharaf, Yasui Yutaka, Geisen Christof, Mitchell Lesley |
|
Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease.
Chinese medical journal 2010 Nov 123 (22): 22. Liu XL, Wang ZJ, Yang Q, Ge HL, Gao F, Liu YY, Shi DM, Zhao YX, Zhou YJ |
|
Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort.
Pharmacogenomics 2010 Oct 11 (10): 1359-65. Haschke-Becher Elisabeth, Kirchheiner Julia, Trummer Olivia, Grünbacher Gerda, Kainz Alexander, Boehm Bernhard O, März Winfried, Renner Wilfri |
|
Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets.
Thrombosis research 2010 Sep 126 (3): e235-7. Le Cam-Duchez Véronique, Frétigny Mathilde, Cailleux Nicole, Gandelin Catherine, Lévesque Hervé, Borg Jeanne-Yvon |
|
The association of protein S Tokushima-K196E with a risk of deep vein thrombosis.
International journal of hematology 2010 Sep 92 (2): 302-5. Ikejiri Makoto, Wada Hideo, Sakamoto Yuko, Ito Naohiko, Nishioka Junji, Nakatani Kaname, Tsuji Akihiro, Yamada Norikazu, Nakamura Mashio, Ito Masaaki, Nobori Tsuto |
|
[Association of polymorphisms of cytochrome P450 2C9 exon 4 and -65G>C with warfarin sensitivity].
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2010 Aug 27 (4): 428-32. Wang Zan-xin, Huang Lei, Cai Heng, Men Jian-long, Wei Min-x |
|
A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.
British journal of clinical pharmacology 2010 Aug 70 (2): 213-21. Lee Su-Jun, Jang Yin Jin, Cha Eun-Young, Kim Ho-Sook, Lee Sang Seop, Shin Jae-Go |
|
VKORC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis.
Thrombosis research 2010 Aug 126 (2): e134-6. Pasmant Eric, de Beauvoir Charlotte, Plessier Aurélie, Labreuche Julien, Bezeaud Ann |
|
Genetic variance in CYP2C8 and increased risk of myocardial infarction.
Pharmacogenetics and genomics 2010 Jul 20 (7): 426-34. Rodenburg Eline M, Visser Loes E, Danser A H Jan, Hofman Albert, van Noord Charlotte, Witteman Jacqueline C M, Uitterlinden André G, Stricker Bruno H |
|
A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
Thrombosis research 2010 Jun 125 (6): e259-64. Wells P S, Majeed H, Kassem S, Langlois N, Gin B, Clermont J, Taljaard |
|
Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
Therapeutic drug monitoring 2010 Jun 32 (3): 338-45. McMillin Gwendolyn A, Melis Roberta, Wilson Andrew, Strong Michael B, Wanner Nathan A, Vinik Russell G, Peters Christopher L, Pendleton Robert |
|
Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Circulation. Cardiovascular genetics 2010 Jun 3 (3): 276-85. Bailey Kristian M, Romaine Simon P R, Jackson Beryl M, Farrin Amanda J, Efthymiou Maria, Barth Julian H, Copeland Joanne, McCormack Terry, Whitehead Andrew, Flather Marcus D, Samani Nilesh J, Nixon Jane, Hall Alistair S, Balmforth Anthony J, |
|
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).
Journal of the American College of Cardiology 2010 Jun 55 (25): 2804-12. Epstein Robert S, Moyer Thomas P, Aubert Ronald E, O Kane Dennis J, Xia Fang, Verbrugge Robert R, Gage Brian F, Teagarden J Russe |
|
Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients.
Circulation journal : official journal of the Japanese Circulation Society 2010 May 74 (5): 977-82. Takeuchi Fumihiko, Kashida Mitsuo, Okazaki Osamu, Tanaka Yuriko, Fukuda Shoji, Kashima Toshitaka, Hosaka Shigeru, Hiroe Michiaki, Kimura Sosuke, Kato Norihi |
- Page last reviewed:Mar 1, 2018
- Page last updated:Jun 13, 2019
- Content source: